Viral hemorrhagic fever risk factors

Jump to navigation Jump to search

Viral hemorrhagic fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Viral Hemorrhagic Fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Viral hemorrhagic fever risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Viral hemorrhagic fever risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Viral hemorrhagic fever risk factors

CDC on Viral hemorrhagic fever risk factors

Viral hemorrhagic fever risk factors in the news

Blogs on Viral hemorrhagic fever risk factors

Directions to Hospitals Treating Viral hemorrhagic fever

Risk calculators and risk factors for Viral hemorrhagic fever risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Risk Factors

VHF should be suspected in febrile persons who, within 3 weeks before onset of fever, have either

1) traveled in the specific local area of a country where VHF has recently occurred;

2) had direct unprotected contact with blood, other body fluids, secretions, or excretions of a person or animal with VHF; or

3) had a possible exposure when working in a laboratory that handles hemorrhagic fever viruses.

The likelihood of acquiring VHF is considered low in persons who do not meet any of these criteria. Even following travel to areas where VHF has occurred, persons with fever are more likely to have infectious diseases other than VHF (e.g., common respiratory viruses, endemic infections such as malaria or typhoid fever). Clinicians should promptly evaluate and treat patients for these more common infections while awaiting confirmation of a VHF diagnosis.

In Africa, transmission of VHF in healthcare settings has been associated with reuse of contaminated needles and syringes and with provision of patient care without appropriate barrier precautions to prevent exposure to virus-containing blood and other body fluids (including vomitus, urine, and stool). The transmission risks associated with various body fluids have not been well defined because most caregivers who have acquired infection had contacts with multiple fluids.

The risk for person-to-person transmission of hemorrhagic fever viruses is greatest during the latter stages of illness when virus loads are highest; latter stages of illness are characterized by vomiting, diarrhea, shock, and, in less than half of infected patients, hemorrhage. No VHF infection has been reported in persons whose contact with an infected person occurred only during the incubation period (i.e., before onset of fever). The incubation period for VHF ranges from 2 days to 3 weeks, depending on the viral agent. There are reports of Ebola virus transmission occurring within a few days after onset of fever; however, the presence of other symptoms in the source patients and the level of exposure to body fluids among secondary cases are unknown in these instances (CDC, unpublished data, 1995). In studies involving three monkeys experimentally infected with Ebola virus (Reston strain), fever and other systemic signs of illness preceded detection of infectious virus in the animals’ pharynx by 2-4 days, in the conjunctiva and on anal swabs by 5-6 days, and in the nares by 5-10 days.

References


Template:WH Template:WS